Grifols, S.A Long-Term Investments 2012-2024 | GRFS

Grifols, S.A long-term investments from 2012 to 2024. Long-term investments can be defined as the aggregate value of debt and or equity investments with maturities or benefits lasting more than one year.

Grifols, S.A Long-Term Investments 2012-2024 | GRFS

Grifols, S.A long-term investments from 2012 to 2024. Long-term investments can be defined as the aggregate value of debt and or equity investments with maturities or benefits lasting more than one year.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$79.8B
Takeda Pharmaceutical (TAK)$43.8B
Merck (MKKGY)$21B
Astellas Pharma (ALPMY)$20.2B
Sandoz Group AG (SDZNY)$19.8B
United Therapeutics (UTHR)$18.3B
Summit Therapeutics (SMMT)$15.8B
Neurocrine Biosciences (NBIX)$12.7B
Shionogi (SGIOY)$12.5B
Catalent (CTLT)$10.8B
Madrigal Pharmaceuticals (MDGL)$7.6B
Jazz Pharmaceuticals (JAZZ)$7.6B
Orion OYJ (ORINY)$6.8B
Corcept Therapeutics (CORT)$6.2B
Ionis Pharmaceuticals (IONS)$6.2B
Crinetics Pharmaceuticals (CRNX)$4.9B
PTC Therapeutics (PTCT)$3.4B
Dyne Therapeutics (DYN)$2.9B
Catalyst Pharmaceuticals (CPRX)$2.9B
Arrowhead Pharmaceuticals (ARWR)$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.7B
Soleno Therapeutics (SLNO)$2.5B
NewAmsterdam Pharma (NAMS)$2.2B
Recursion Pharmaceuticals (RXRX)$2B
Centessa Pharmaceuticals (CNTA)$1.9B
Harrow (HROW)$1.9B
Ocular Therapeutix (OCUL)$1.7B
Xencor (XNCR)$1.7B
ARS Pharmaceuticals (SPRY)$1.7B
BioCryst Pharmaceuticals (BCRX)$1.6B